Pamela L. Clemens

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 231 citations

Hematological Malignancy, Surgical Oncology, Medicine +6

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Tineke Casneuf, Xu Steven Xu, Homer Adams et al. · Blood Advances · 2017 · 218 citations · Full text

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Ajai Chari, Joaquín Martínez‐López, María‐Victoria Mateos et al. · Blood · 2019 · 129 citations · Full text

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

Christopher R. McCudden, Amy Axel, Dominique Slaets et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2016 · 116 citations · Full text

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos et al. · Blood · 2019 · 114 citations · Full text